



Preface
Localized prostate cancer



Arnon Krongrad, MD, FACS
Guest Editor

Are we making progress in the treatment of localized prostate cancer? This is a difficult question to answer. We are in a technological age, and we see technological progress: new biochemical markers, new imaging, new ways of targeting radiation. As we see the wide dissemination of laparoscopic radical prostatectomy, we can tangibly feel technology's power to change.

However, for all the aesthetic beauty of technology, many clinical ambitions remain frustrated by what is often an elusive and tenacious disease. Our patients want certainty, yet we speak in probability. Should they have a repeat biopsy? Should they have adjuvant therapy? Will they regain erections? We're never really sure.

For all our technological advances, we continue to live in a clinical world with seemingly infinite permutations and possibilities. For all our progress, we daily reaffirm that we are doctors treating people who are vulnerable and afraid

and we sense the humility that clinical medicine requires.

To whom is this issue dedicated? The list would be too long to fit here. Certainly the authors of the articles, who have struggled to understand and present what is known today, deserve credit and gratitude for their selflessness and contribution. And so many doctors, nurses, and friends, who have inspired us to do more, deserve credit. But more than anyone, it is our brothers, colleagues, and friends who have hurt, bled, and died because of prostate cancer who motivate us to consume what is known and discover what is not yet known. This issue is dedicated to our patients.

Arnon Krongrad, MD
President, The Prostate Cancer Project
21110 Biscayne Boulevard, Suite 208
Aventura, FL 33180, USA

E-mail address: info@krongrad-urology.com